Diag2Tec is a preclinical CRO devoted to Hematological Malignancies, especially Multiple Myeloma (MM).
We focus on in vitro Drug Testing in Multiple Myeloma, Lymphoma, Leukemia derived Cell Lines and Primary Cells from patients. With our Drug Testing Services and ChimioFx Platforms, our mission is to provide efficient treatment solutions and precision medicine tools for patients suffering from Hematological Malignancies. We support biotech and pharmaceutical companies to focus their preclinical drug development on the right molecules in the right indications.
In recent years, Next Generation Sequencing (NGS) studies of hematological malignancies have allowed a finer characterization of the cancer cells underlying these diseases by further highlighting their heterogeneity and revealing novel molecular alterations. Our team has developed different tools and algorithms to analyze these data and answer to specific medical challenges.
DIAG2TEC has not received any reviews.
DIAG2TEC has not received any endorsements.